Fust Matthew K Insider Trading Activity

Average Profitability
10.12%
Insider Buys Quantity
2
Insider Buys Sum
$205,604.40
Insider Sells Quantity
23
Insider Sells Sum
$7.46M

Insider Activity of Fust Matthew K

Biography of Fust Matthew K

No biography is available at this moment.

2024-10-18SaleNeumora Therapeutics, Inc. Common Stock
NMRA
director
14,049
0.0149%
$17.03$239,319-89.93%
2024-10-17SaleNeumora Therapeutics, Inc. Common Stock
NMRA
director
7,739
0.0082%
$17.01$131,643-90.18%
2024-03-07SaleUltragenyx Pharmaceutical Inc.
RARE
director
12,195
0.0147%
$50.88$620,443-11.27%
2021-11-04SaleAtara Biotherapeutics, Inc.
ATRA
director
13,354
0.0134%
$19.50$260,403-63.25%
2020-07-06SaleUltragenyx Pharmaceutical Inc.
RARE
director
6,181
0.0106%
$90.00$556,290+22.94%
2020-07-01SaleUltragenyx Pharmaceutical Inc.
RARE
director
5,000
0.0083%
$85.00$425,000+25.99%
2020-05-18SaleUltragenyx Pharmaceutical Inc.
RARE
director
1,875
0.0032%
$75.00$140,625+46.65%
2020-04-22SaleUltragenyx Pharmaceutical Inc.
RARE
director
1,875
0.0031%
$65.00$121,875+46.16%
2019-12-24SaleJourney Medical Corporation
DERM
director
3,000
0.0373%
$15.00$45,000
2019-12-12SaleJourney Medical Corporation
DERM
director
3,000
0.0298%
$12.00$36,000
2019-09-12SaleJourney Medical Corporation
DERM
director
6,000
0.0436%
$8.77$52,636
2019-02-06SaleMacroGenics, Inc.
MGNX
director
13,848
0.0294%
$24.77$342,946-43.73%
2018-10-19SaleJourney Medical Corporation
DERM
director
4,000
0.0456%
$13.75$55,000
2018-05-30SaleUltragenyx Pharmaceutical Inc.
RARE
director
12,638
0.0253%
$72.00$909,939-8.67%
2018-05-14SaleAtara Biotherapeutics, Inc.
ATRA
director
12,286
0.0272%
$43.57$535,301-13.66%
2014-11-25PurchaseJourney Medical Corporation
DERM
director
6,000
0.0833%
$16.77$100,604
2014-01-30PurchaseUltragenyx Pharmaceutical Inc.
RARE
director
5,000
0.0115%
$21.00$105,000+10.12%
Total: 17
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.